Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 250Lymphoma 128Leukemia, Myeloid, Acute 103Lymphoma, Non-Hodgkin 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Neoplasms, Plasma Cell 91Myelodysplastic Syndromes 91Leukemia 79Hodgkin Disease 78Lymphoma, Large B-Cell, Diffuse 66Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Mantle-Cell 59Lymphoma, Follicular 57Neuroblastoma 44Burkitt Lymphoma 44Lymphoma, Large-Cell, Immunoblastic 40Lymphoma, B-Cell, Marginal Zone 37Recurrence 34Myeloproliferative Disorders 32Hematologic Neoplasms 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Immunoglobulin Light-chain Amyloidosis 29Leukemia, Myeloid, Accelerated Phase 25Leukemia, Myeloid, Chronic-Phase 24Congenital Abnormalities 24Leukemia, Myelomonocytic, Chronic 23Graft vs Host Disease 23Dendritic Cell Sarcoma, Interdigitating 21Waldenstrom Macroglobulinemia 20Melanoma 20

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Melphalan × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡